2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests.

A group of 146 experts representing 29 organizations and professional societies met September 18-19, 2006, in Bethesda, MD, to develop revised evidence-based, consensus guidelines for managing women with abnormal cervical cancer screening tests. Recommendations for managing atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion (LSIL) are essentially unchanged. Changes were made for managing these conditions in adolescents for whom cytological follow-up for 2 years was approved. Recommendations for managing high-grade squamous intraepithelial lesion (HSIL) and atypical glandular cells (AGC) also underwent only minor modifications. More emphasis is placed on immediate screen-and-treat approaches for HSIL. Human papillomavirus (HPV) testing is incorporated into the management of AGC after their initial evaluation with colposcopy and endometrial sampling. The 2004 Interim Guidance for HPV testing as an adjunct to cervical cytology for screening in women 30 years of age and older was formally adopted with only very minor modifications.

[1]  David R. Scott,et al.  The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. , 2005, Journal of the National Cancer Institute.

[2]  M. Sadeghi,et al.  Comparison of two signal-amplification DNA tests for high-risk HPV as an aid to colposcopy. , 2002, The Journal of reproductive medicine.

[3]  M. Zahurak,et al.  Clinical utility of atypical glandular cells (AGC) classification: cytohistologic comparison and relationship to HPV results. , 2007, Gynecologic oncology.

[4]  C. Clavel,et al.  Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women , 2001, British Journal of Cancer.

[5]  G. Orth,et al.  Human Papillomavirus Testing in Women With Mild Cytologic Atypia , 2000, Obstetrics and gynecology.

[6]  K. Straif,et al.  Carcinogenicity of human papillomaviruses. , 2005, The Lancet. Oncology.

[7]  S. Girlando,et al.  HPV triage of women with atypical squamous cells of undetermined significance: a 3‐year experience in an Italian organized programme , 2005, Cytopathology : official journal of the British Society for Clinical Cytology.

[8]  R. Greenblatt,et al.  Evolution of Cervical Abnormalities Among Women With HIV‐1: Evidence From Surveillance Cytology in the Women's Interagency HIV Study , 2001, Journal of acquired immune deficiency syndromes.

[9]  Atypical Squamous Cells of Undetermined Significance: Human Papillomavirus Testing in Adolescents , 2005, Obstetrics and gynecology.

[10]  G. Pawlick,et al.  Human Papillomavirus DNA Testing in Routine Clinical Practice for Prediction of Underlying Cervical Intraepithelial Neoplasia 2/3+ at Initial Evaluation and in Follow-up of Women with Atypical Glandular Cell Papanicolaou Tests , 2006 .

[11]  E. P. Dellinger,et al.  Purpose of quality standards for infectious diseases. Infectious Diseases Society of America. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  M A Kish,et al.  Guide to development of practice guidelines. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  M. Schiffman,et al.  Adding a test for human papillomavirus DNA to cervical-cancer screening. , 2003, The New England journal of medicine.

[14]  J. Dillner,et al.  Virologic versus cytologic triage of women with equivocal Pap smears: A meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia , 2004 .

[15]  Human papillomavirus testing using hybrid capture II with surepath collection , 2006, Cancer.

[16]  J. Peto,et al.  Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort , 2004, British Journal of Cancer.

[17]  J. T. Cox,et al.  Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening , 2004, Obstetrics and gynecology.

[18]  G. Bigras,et al.  The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13 842 women , 2005, British Journal of Cancer.

[19]  A. Moscicki,et al.  Regression of low-grade squamous intra-epithelial lesions in young women , 2004, The Lancet.

[20]  R. Hiatt,et al.  Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. , 1999, JAMA.

[21]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, , 2006 .

[22]  A. Moscicki,et al.  American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer , 2002, CA: a cancer journal for clinicians.

[23]  Frequency of Cervical Smear Abnormalities Within 3 Years of Normal Cytology , 2000, Obstetrics and gynecology.

[24]  T. Wright.  HPV DNA Testing for Cervical Cancer Screening , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[25]  J. Cangiarella,et al.  Reporting endometrial cells in women 40 years and older: assessing the clinical usefulness of Bethesda 2001. , 2005, American journal of clinical pathology.

[26]  P. Saigo,et al.  Smears diagnosed as ASCUS: Interobserver variation and follow‐up , 2001, Diagnostic cytopathology.

[27]  R. Alvarez,et al.  High-Risk Human Papillomavirus and Cervical Intraepithelial Neoplasia at Time of Atypical Squamous Cells of Undetermined Significance Cytologic Results in a Population with Human Immunodeficiency Virus , 2004, Journal of lower genital tract disease.

[28]  H. Ngan,et al.  A retrospective review on atypical glandular cells of undetermined significance (AGUS) using the Bethesda 2001 classification. , 2003, Gynecologic oncology.

[29]  J. Shwayder,et al.  A “See and Treat” Management for High-Grade Squamous Intraepithelial Lesion Pap Smears , 2003, Journal of lower genital tract disease.

[30]  A. Guyot,et al.  Evaluation of adjunctive HPV testing by Hybrid Capture II® in women with minor cytological abnormalities for the diagnosis of CIN2/3 and cost comparison with colposcopy , 2003, BMC infectious diseases.

[31]  K. Syrjänen,et al.  Human papillomavirus DNA detection and histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears. , 2004, Gynecologic oncology.

[32]  B. Jones,et al.  Follow-up of abnormal gynecologic cytology: a college of American pathologists Q-probes study of 16132 cases from 306 laboratories. , 2000, Archives of pathology & laboratory medicine.

[33]  T. Wright,et al.  Cost-Effectiveness of Human Papillomavirus DNA Testing for Cervical Cancer Screening in Women Aged 30 Years or More , 2004, Obstetrics and gynecology.

[34]  T. Wright,et al.  Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. , 2002, JAMA.

[35]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[36]  S. Ciatto,et al.  Interlaboratory reproducibility of atypical squamous cells of undetermined significance report: a national survey , 2003, Cytopathology : official journal of the British Society for Clinical Cytology.

[37]  M. Sherman,et al.  Qualification of ASCUS. A comparison of equivocal LSIL and equivocal HSIL cervical cytology in the ASCUS LSIL Triage Study. , 2001, American journal of clinical pathology.

[38]  M. Sherman,et al.  Atypical glandular cells of undetermined significance (AGUS): Interobserver reproducibility in cervical smears and corresponding thin-layer preparations. , 2002, American journal of clinical pathology.

[39]  Li Zhi-gang,et al.  2006 Consensus Guidelines for the Management of Women with Abnormal Cervical Cancer Screening Tests , 2008 .

[40]  J. T. Cox,et al.  Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). , 2002, Journal of the National Cancer Institute.

[41]  T. Wright,et al.  2006 Consensus Guidelines for the Management of Women With Abnormal Cervical Screening Tests , 2007, Journal of lower genital tract disease.

[42]  B. Beaty,et al.  Management of the Minimally Abnormal Papanicolaou Smear in Pregnancy , 2001, Journal of lower genital tract disease.

[43]  J. Cuzick,et al.  Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. , 2006, Journal of the National Cancer Institute.

[44]  I. Eltoum,et al.  Reflex human papilloma virus infection testing detects the same proportion of cervical intraepithelial neoplasia grade 2–3 in young versus elderly women , 2005, Cancer.

[45]  F. Montz,et al.  See-and-treat in the management of high-grade squamous intraepithelial lesions of the cervix: a resource utilization analysis. , 1999, Obstetrics and gynecology.

[46]  S. Pambuccian,et al.  Cytologic–histologic correlation of screening and diagnostic Papanicolaou tests , 2006, Diagnostic cytopathology.

[47]  W. Prendiville,et al.  Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. , 2007, Gynecologic oncology.

[48]  Lydia P. Howell,et al.  NATURAL HISTORY OF CERVICAL SQUAMOUS INTRAEPITHELIAL LESIONS: A META‐ANALYSIS , 1998, Obstetrics and gynecology.

[49]  Thomas C Wright,et al.  2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities. , 2002, Journal of lower genital tract disease.

[50]  U Menon,et al.  Management of women who test positive for high-risk types of human papillomavirus: the HART study , 2003, The Lancet.

[51]  Elizabeth R Unger,et al.  Prevalence of HPV infection among females in the United States. , 2007, JAMA.

[52]  C. Heilig,et al.  Effect of HIV infection on atypical squamous cells of undetermined significance. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  J. T. Cox,et al.  Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. , 2003, American journal of obstetrics and gynecology.

[54]  M. Schiffman,et al.  Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. , 2003, American journal of obstetrics and gynecology.

[55]  T. Rohan,et al.  Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. , 2001, JAMA.

[56]  L. Massad,et al.  Biopsy correlates of abnormal cervical cytology classified using the Bethesda system. , 2001, Gynecologic oncology.

[57]  S. Kjaer,et al.  The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. , 2006, Cancer research.

[58]  A. Hayanga.  Distribution of human papillomavirus types in ThinPrep papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes , 2006, Cancer.

[59]  M. Schiffman,et al.  Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. , 2001, JAMA.

[60]  K. Anastos,et al.  HPV testing for triage of HIV-infected women with papanicolaou smears read as atypical squamous cells of uncertain significance. , 2004, Journal of women's health.

[61]  D. Wilbur,et al.  Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. , 2009, Archives of pathology & laboratory medicine.

[62]  W. Lawrence,et al.  Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). , 2006, Journal of the National Cancer Institute.

[63]  K. Cooper,et al.  Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes , 2006, Cancer.

[64]  M. Schiffman,et al.  Chapter 5: Updating the natural history of HPV and anogenital cancer. , 2006, Vaccine.

[65]  J. Cuzick,et al.  Overview of the European and North American studies on HPV testing in primary cervical cancer screening , 2006, International journal of cancer.

[66]  B. Jones,et al.  Quality management in gynecologic cytology using interlaboratory comparison. , 2009, Archives of pathology & laboratory medicine.

[67]  R. Alvarez,et al.  A Prospective Evaluation of "See and Treat" in Women with HSIL Pap Smear Results: Is This an Appropriate Strategy? , 2005, Journal of lower genital tract disease.

[68]  J. Dillner,et al.  Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. , 2006, Vaccine.

[69]  J. Felix,et al.  Triage of Atypical Squamous Cells of Undetermined Significance With Hybrid Capture II: Colposcopy and Histologic Human Papillomavirus Correlation , 2003, Obstetrics and gynecology.

[70]  Joan L. Walker.  A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. , 2003, American journal of obstetrics and gynecology.

[71]  A. Glass,et al.  Diagnoses and outcomes in cervical cancer screening: a population-based study. , 2004, American journal of obstetrics and gynecology.

[72]  A. Burchell,et al.  Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. , 2006, Vaccine.

[73]  J. Sorosky,et al.  Dysplasia Associated With Atypical Glandular Cells on Cervical Cytology , 2005, Obstetrics and gynecology.

[74]  Mark Sherman,et al.  The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.

[75]  J. Wardle,et al.  Chapter 10: New dimensions in cervical cancer screening. , 2006, Vaccine.

[76]  J. Wardle,et al.  New dimensions in cervical cancer screening , 2006 .

[77]  A. Moriarty,et al.  Endometrial Cells in Cervical Cytology: Review of Cytological Features and Clinical Assessment , 2006, Journal of lower genital tract disease.

[78]  Joakim Dillner,et al.  Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. , 2004, Journal of the National Cancer Institute.

[79]  Thomas C Wright,et al.  Effective cervical neoplasia detection with a novel optical detection system: a randomized trial. , 2007, Gynecologic oncology.

[80]  E. P. Dellinger,et al.  Purpose of Quality Standards for Infectious Diseases , 1994 .

[81]  C. Desimone,et al.  Rate of Pathology From Atypical Glandular Cell Pap Tests Classified by the Bethesda 2001 Nomenclature , 2006, Obstetrics and gynecology.

[82]  Deqin Sun,et al.  Atypical glandular cells of undetermined significance. Outcome predictions based on human papillomavirus testing. , 2004, American journal of clinical pathology.